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ihe Heart Failure Society of America (HFSA) is a multi-
isciplinary organization of health care professionals dedi-
ated to promoting research and education, with the pri-
ary goal of prevention and treatment of heart failure.
urthermore, the HFSA engages in the development of
omprehensive patient care guidelines and serves as a
esource for the government, health care industry, and
roviders to affect heart failure-related policy. Importantly,
he HFSA has established a fellowship program to support
oung academic physicians focusing on heart failure and has
upported the development of a professional certification
rogram in advanced heart failure and transplant cardiology.
The 11th Annual Scientific Meeting, co-chaired by Drs.
andeep R. Mehra and Howard A. Rockman, was at-
ended by approximately 2,700 cardiologists, surgeons,
urses, pharmacists, and allied health professionals repre-
enting academia, government, and industry. The program
ncluded presentations on advances and controversies in
asic, translational, and clinical research, clinical care, and
ublic policy related to heart failure. This is a report of the
eeting highlights.
pening Session:
mpowering Innovation in Research
he opening plenary session focused on the challenges
acing progress in research. Gail D. Pearson, Branch Chief,
eart Development and Structural Diseases Division, Na-
ional Heart, Lung, and Blood Institute (NHLBI), dis-
ussed “The National Institutes of Health (NIH) Road
ap as an Optimal Heart Failure Research Catalyst.” The
IH blueprint for facilitating research over the next decade
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Manuscript received November 2, 2007; accepted November 8, 2007.as developed by a conglomeration of 23 work groups,
ncluding one on heart failure. The plan’s overarching goal
s to improve our understanding of the molecular and
hysiologic basis of disease, the clinical mechanisms of
isease, and the process of translating research into clinical
ractice. Priorities in the arena of heart failure include study
f the triggers and modifiers of heart failure, the effects of
reatment on disease progression, and improving our under-
tanding of the heart failure epidemic. As an example,
pecific NHLBI-supported heart failure studies will seek to
xplore the rationale for diuretic dosing in acute heart
ailure, the use of ultrafiltration in acute decompensated
eart failure with cardiorenal syndrome, and surgical tech-
iques for mitral valve repair in severe left ventricular failure.
r. Pearson stressed that the NHLBI shares the goals,
ission, and sense of urgency of the HFSA.
Andrew R. Marks (Columbia University, New York,
ew York) acknowledged the important partnership of the
HLBI with basic scientists but also critiqued the funding
risis at the NIH in his talk, “Challenges Facing the Basic
cience Investigator.” Despite the importance of basic
cience research for the identification of mechanisms of
isease and novel therapeutic targets, Dr. Marks under-
cored the difficulties for researchers who are “riding the
IH funding roller coaster.” He said that it was ironic to
bserve that because the NIH budget doubled to fund the
oadmap, it has been significantly harder for individual
nvestigators to get grants. Junior investigators and under-
epresented minorities, including women, have been partic-
larly hard hit. In this environment, research needs to be
irtually certain of success to be funded. Creative or risky
roposals will not be funded. This policy diminishes scien-
ific advances. To solve the funding problem, Dr. Marks
roposed shelving the roadmap and streamlining the appli-
ation process for NIH funding. The issue is not the
oadmap, but the importance of restoring funds to
ndividual-initiated research. Large clinical studies that
equire hundreds of millions of dollars should be supported
n partnership with industry, he said.
Robert M. Califf (Duke University, Durham, North
arolina) addressed research challenges from the perspec-
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January 22, 2008:320–7 Highlights of 2007 HFSA Scientific Meetingive of a clinical investigator. These challenges include lack
f acceptance as a concrete valued discipline, shortage of
apable mentoring, bureaucratic hurdles and sparse infra-
tructure, and inadequate funding. He asked for a renewed
ocus on development of clear definitions of what consti-
utes excellence and expertise in clinical research. He
uipped that clinical researchers suffer from “a Rodney
angerfield syndrome” and feel undervalued. Academic
nstitutions prize basic research, whereas clinical research is
elegated to the realm of a “bystander hobby.” Top academic
enters often fail to grant tenure to clinical researchers,
eading to a culture that does not nourish clinical research.
he problem is further compounded because efforts toward
linical research remain unfunded and require subsidy via
dditional clinical activity. In fact, by virtue of awarding
reater funding to basic science, the NIH has reinforced this
ituation. Thus, a strong NIH is needed—one willing to
tand up to bureaucracy and industry and to facilitate
ffective partnerships. Public–private partnerships in which
esources are pooled are critical to the success of clinical
esearch, Dr. Califf concluded.
ecent and Late-Breaking Trials
his session highlighted results from 4 trials: 2 on implant-
ble heart failure devices, one on use of transtelephonic
onitoring in the management of heart failure patients, and
ne on the use of a vasopressin V2 receptor blocker in
ecompensated heart failure.
esults of the PROSPECT (Predictors of Response to
RT) trial. Eugene S. Chung (Ohio Heart and Vascular
enter, Cincinnati, Ohio) presented the results of the
ROSPECT trial, which studied the ability of echocardi-
graphy measurements to predict response to cardiac resyn-
hronization therapy (CRT). Although CRT has been
hown to reduce morbidity and mortality in well-selected
atients (with systolic heart failure and a widened QRS
nterval on the surface electrocardiogram) who remain
ersistently symptomatic despite optimal medical therapy,
s many as 30% demonstrate poor to no response to this
herapy. Single-center studies support the use of echocar-
iographic measures of mechanical dyssynchrony to identify
esponders to CRT and to optimize therapeutic implemen-
ation. The PROSPECT trial studied 12 pre-defined echo-
ardiography parameters of mechanical dyssynchrony in the
etting of a prospective, observational, nonrandomized,
ulticenter trial. The primary end points, analyzed sepa-
ately at 6 months were: 1) improvement in clinical com-
osite score defined as survival without heart failure hospi-
alizations or heart failure-related CRT discontinuation and
ew York Heart Association (NYHA) functional class
mprovement or improved patient global assessment; or 2)
eduction of left ventricular end-systolic volume of 15%.
The trial enrolled 426 patients with NYHA functional
lass III or IV heart failure, a left ventricular ejection
raction 35%, and QRS duration 130 ms who were pmplanted with either a CRT or a CRT-defibrillator device.
atients were followed at 1, 3, and 6 months, and echocar-
iography measurements were made at baseline and at the
-month follow-up. Each participating center was trained
n a protocol for echo assessments, and analysis was adju-
icated by a core laboratory. Results demonstrated that 69%
mproved, 15% were unchanged, and 16% clinically wors-
ned. With regard to left ventricular end-systolic volume,
6% showed a 15% reduction, 9% increased in size, and
5% fell in between. The rate of clinical improvement was
6% among patients with nonischemic disease and 64% in
atients with ischemic heart failure (p  0.01). Reverse
emodeling was seen in 56% overall, 63% among nonisch-
mic patients, and 50% among ischemic patients (p 0.03).
ore important, however, was the finding of a lack of
redictive value of individual measures of echocardiographic
yssynchrony to define these clinical responses observed.
urthermore, marked discrepancy was observed between the
ore laboratory adjudication and local centers in their
nterpretation of tissue Doppler imaging measurements and
hose pertaining to interventricular delay (varied by 50% and
0%, respectively). This result affirmed the contention that
ntil better standardization and test–test reliability of echo-
ardiography parameters of dyssynchrony can be developed,
his technique is not ready for prime time use to guide
ecisions for CRT.
andomized clinical trial of the clinical effects of en-
anced heart failure monitoring using a computer-based
elephonic monitoring system in older minorities and
omen. Ozlem Z. Soran (University of Pittsburgh, Pitts-
urgh, Pennsylvania) presented the results of this study
ssessing the efficacy of a home monitoring system on heart
ailure outcomes. Although several earlier studies have
xpressed ebullience for the use of home telemonitoring,
hey have not enrolled elderly patients, women, and minor-
ties with reasonable penetration to draw conclusions for
fficacy in these populations. This multicenter, randomized,
ontrolled clinical trial enrolled 315 Medicare-eligible pa-
ients—more than 60% women, one-third Hispanics, and
ore than 40% African Americans—with heart failure
econdary to systolic dysfunction. All had been hospitalized
or heart failure within 6 months of randomization and had
ymptoms despite optimal medical treatment. The patients,
ho were cared for by primary care physicians in
ommunity-based clinics, were randomized 1:1 to either the
lere Day Link Heart Failure Monitoring System (Alere
edical, Inc., Reno, Nevada) or standard heart failure care.
atients in both groups received optimal medical care (over
5% were taking beta-blockers, and over 90% were taking
iuretics). The monitoring system consisted of an electronic
cale with a response system, programmed to ask patients
eart failure questions. Patient weight data and answers to
he questions were transmitted via telephone line to a
emote database monitored by trained nurses. The nurses
eported significant changes directly to the primary care
hysicians. Standard care consisted of one-on-one educa-
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Highlights of 2007 HFSA Scientific Meeting January 22, 2008:320–7ion, an effort to use evidenced-based optimal medical
reatment, and use of a digital home scale. Patients were
ollowed in the clinic at baseline and at 6 months as well as
y telephone contact at 30 days and 3 months by nonmed-
cal personnel blinded to treatment assignment. The pri-
ary end point was cardiovascular death or rehospitalization
or heart failure within 6 months of enrollment. Among
ehospitalized patients, length of stay was also considered to
e a primary end point. Secondary end points included
-month all-cause hospitalization, 6-month heart failure
ospitalization, emergency room visits, change in functional
tatus, and quality-of-life measurements.
The study showed that use of the system had no signif-
cant impact on the primary or secondary end points. The
esults were surprising to Sharon A. Hunt (Stanford Uni-
ersity, Palo Alto, California) session co-chair, who said,
We really want to hear that heart failure management
ystems work and are accustomed to hearing that they do
ork.” Dr. Ozlem said that although remote monitoring
ight be efficacious in a different setting, the results are not
niversal. She also suggested that because both groups were
lready receiving optimal medical care and good patient
ducation, there was little room for improved outcomes
hrough a disease management program.
cute hemodynamic effects of tolvaptan, a vasopressive
2-receptor blocker, in patients with symptomatic heart
ailure and systolic dysfunction: the ECLIPSE (Effect of
olvaptan on Hemodynamic Parameters in Subjects with
eart Failure) international, multicenter, randomized,
lacebo-controlled trial. James E. Udelson (Tufts Univer-
ity, Boston, Massachusetts) presented the results of the
CLIPSE trial, which studied the effects of tolvaptan, a V2
asopressin-receptor antagonist, on hemodynamics and
uid balance in patients with advanced heart failure and left
entricular dysfunction. In the previously reported EVEREST
Efficacy of Vasopressin Antagonism in Heart Failure Trial)
tudy, tolvaptan was shown to improve the signs and
ymptoms of congestion (dyspnea, orthopnea, and edema)
nd reduce body weight without adversely affecting long-
erm outcomes. The ECLIPSE trial was a multicenter,
andomized, double-blind, placebo-controlled, dose-
anging study of a single administration of tolvaptan. The
rimary objective was to compare the effects of tolvaptan
nd placebo on pulmonary capillary wedge pressure
PCWP). Secondary objectives were the effects of tolvaptan
ompared with placebo on a number of pharmocodynamic
ariables. A total of 181 patients with NYHA functional
lass III to IV heart failure, who were on a stable regimen of
eart failure drug therapy and had a baseline PCWP 18
m, were randomized to receive an oral dose of 15, 30, or
0 mg tolvaptan or placebo. Patients received their concom-
tant heart failure medications no longer than 2 h before
nsertion of a pulmonary artery catheter. The catheter could
e inserted from 2 to 20 h before administration of the study
ose. Urine output measurements were also started 2 h
efore drug administration. Hemodynamic assessments tere made at varying points up to 12 h, and safety was
ssessed out to 7 days.
Results showed an early reduction in PCWP in all of the
roups, but the placebo group drifted back to baseline.
here was a statistically significant reduction in the PCWP
n all of the tolvaptan groups, but no clear dose–response
elationship. The peak change in PCWP at any time
etween 3 and 8 h was statistically significant but modest
ompared with the placebo group. Similarly, there were
ignificant though modest reductions in the mean pulmo-
ary artery pressure compared with placebo, again with no
ose–response curve. Dr. Udelson surmised that placement
f the pulmonary artery catheter itself had a vasodilator
ffect, resulting in the drop in PCWP in the placebo group.
here were modest reductions in right atrial pressure in the
olvaptan groups. There was a dose-dependent and highly
ignificant increase in urine output. Urine osmolality de-
reased significantly in the tolvaptan groups with no dose
esponse. Tolvaptan was generally well tolerated, with
dverse effects slightly higher in the higher-dose groups.
In summary, the results of the ECLIPSE study demon-
trated that acute antagonism of vasopressin V2 receptors
esults in favorable, although often modest, hemodynamic
nd renal effects in heart failure patients. They also provide
mechanistic explanation for the changes in dyspnea seen in
he EVEREST trial but create new questions about the
ong-term significance of such short-term gains, because the
VEREST trial demonstrated no difference in primary
utcomes between tolvaptan- and placebo-treated groups at
4 months.
mpact of atrial pacing on quality of life in the DAVID
Dual-Chamber and VVI Implantable Defibrillator) II
rial. James R. Cook (Baystate Medical Center, Spring-
eld, Massachusetts) presented the DAVID II study, a
rospective, multicenter, noninferiority study in which the
ffect of atrial pacing was compared with ventricular pacing
n patients with an implantable cardioverter-defibrillator
ICD) in the setting of left ventricular dysfunction but with
o indication for bradycardia pacing. The primary end point
as death or heart failure hospitalization; the secondary end
oint was quality of life. The DAVID II study was
redicated on the results of the DAVID I study, which
uggested dual-chamber pacing resulted in more heart
ailure-related hospitalizations.
A total of 600 patients with primary and secondary
ndications for an ICD and a left ventricular ejection
raction 40% were randomized to receive either atrial
acing at AAI-70 or ventricular backup pacing at VVI-40.
lmost all of the patients were NYHA functional class I or
I at the time of enrollment. Background medical therapy
as excellent. Results of the study found that at 24-month
ollow-up there was very little ventricular pacing in the VVI
roup and approximately 50% atrial pacing in the AAI
roup. There was no significant difference between the 2
roups for the primary end point of death or rehospitaliza-
ion for new or worsened heart failure. Similarly, there was
n
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January 22, 2008:320–7 Highlights of 2007 HFSA Scientific Meetingo difference when subgroup results were considered. There
ere no significant differences in the quality-of-life second-
ry end point results. In conclusion, the DAVID II study
ound that atrial-based pacing (AAI-70) is not substantially
orse and is likely equivalent to ventricular back-up pacing
VVI-40) in patients with an LV dysfunction and an ICD
nd no indication for antibradycardia pacing.
ebates
re stem cells to repair the broken heart ready for prime
ime? The use of stem cells to treat heart failure was hotly
ebated by Steven R. Houser (Temple University, Philadel-
hia, Pennsylvania) and Charles E. Murry (University of
ashington, Seattle, Washington). Dr. Houser argued that
urrent dogma that the heart has no renewal capacity is
undamentally incorrect. Experiments in his laboratory have
emonstrated that bone marrow-derived stem cells can be
ransformed into truly functioning myocytes in a rat tissue
odel. Although it is not known if this would occur in
uman hearts, it does provide a paradigm for new myocyte
ormation in the heart. Dr. Houser remarked that animal
nd human studies involving bone marrow cell therapies are
afe, and there is emerging evidence for efficacy signals. In
is opinion, the question should be not whether stem cell
herapy is ready for prime time, but rather what should we
ry next?
Dr. Murry argued that “prime time” should mean that
afety has been convincingly demonstrated and that the
herapy is ready for widespread clinical use. Both safety and
fficacy must be demonstrated in randomized, blinded,
lacebo-controlled trials using hard end points. His conten-
ion was that current clinical trials have fallen short of
llowing us to develop a conviction about stem cell therapy.
uestions remain about the right cell type as well as the
ppropriate patient in whom these cells should be used. He
ointed out that as yet, we do not know exactly how this
herapy works. He asserted that it is a fallacy to assume that
tem cells re-muscularize the heart. It is also a fallacy that
tem cell therapy is safe and easy. Complications include
entricular arrhythmias with skeletal muscle grafts, calcifi-
ation with bone marrow stem cells, and microemboli with
ntracoronary administration of stem cells. Phase I clinical
rials of stem cells have not been sufficiently powered to
emonstrate efficacy. Randomized controlled clinical trials
ave yet to demonstrate a robust proof of concept, Dr.
urry concluded.
hould “functional” mitral regurgitation in severe heart
ailure be repaired? James S. Gammie (University of
aryland, Baltimore, Maryland) presented the case in favor
f surgical repair of secondary mitral regurgitation (MR).
itral regurgitation (i.e., geometric MR occurring as a
onsequence of ventricular remodeling, not degenerative
R) is common in patients with heart failure and is
ssociated with a poor prognosis. Mitral regurgitation be-
ets more MR which in turn worsens ventricular function. The cycle can be interrupted with an annular ring in a
rocedure that takes about 1.5 to 2 h to perform and can be
ccomplished with low morbidity and mortality in experi-
nced hands. Use of a rigid ring and undersizing has also
een shown to provide a durable repair in more recent
tudies. These studies provide convincing evidence that
itral valve repair is safe, effective, and durable and im-
roves patient symptoms. However, we do not know if the
rocedure increases survival, Dr. Gammie concluded.
Michael A. Acker (University of Pennsylvania, Philadel-
hia, Pennsylvania) opened his opposing arguments by
tating that amelioration of MR in heart failure was a
eductive hypothesis because of the negative prognostic
mplications associated with its presence. However, benefi-
ial outcomes have not been clearly documented. We do not
now if the ventricle is continuing to dilate, causing new
R, or if the reverse is true and recurrent MR is causing
dditional ventricular remodeling. We need objective data
n symptom improvement, reverse remodeling, and recur-
ence. The surgical literature on MR repair is limited and
redominantly anecdotal. Studies are generally small, there
s no control group, they are not randomized, and they have
hort follow-up. In studies where MR has been corrected,
he coronary vessels have also been concomitantly revascu-
arized, and therefore we cannot claim that improvements
ere due to mitral valve repair alone. Recurrence is a
roblem with ring repairs, and the benefits on survival
emain uncertain. Mitral valve replacement, rather than
epair, may eliminate recurrence. The current state of affairs
rgues for the development of well-constructed randomized
rials designed to answer these questions.
rogress in the HFSA Practice Guidelines
he HFSA published its “Comprehensive Heart Failure
ractice Guidelines” in 2006 and is committed to updating
he document annually. The guidelines session detailed
spects of the evaluation and revision process, including
fforts to improve the usability and accessibility of the
uidelines. It also introduced the new initiatives of the
uidelines process, focusing on the development of guide-
ines for the genetic evaluation of inheritable cardiomyop-
thy and for chemotherapy-related cardiotoxicity.
The HFSA Guidelines Committee Chair, JoAnn Lin-
enfeld (University of Colorado, Denver, Colorado), began
y addressing the question, “Have We Met the Guidelines
or Guidelines?” The HFSA has initiated the revision and
pdate process by systematically reviewing the recent liter-
ture related to each of the 16 sections of the 2006
uidelines. This literature forms the basis for reviewing
ections in a timely manner using an evidence-based ap-
roach. In addition, the HFSA is using a policy to avoid
onflicts, not just declare them. Access has been provided
hrough an easily navigated website and a Pocket Guide (1).
he HFSA hopes to include primary care and greater
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Highlights of 2007 HFSA Scientific Meeting January 22, 2008:320–7atient access to the guidelines as we move forward,
specially by using the Internet portal capability.
Alan B. Miller (University of Florida, Jacksonville, Flor-
da) reported on updates and additions to the 2006 guide-
ines. Subjects currently under discussion for changes in-
lude: heart failure prevention, endocarditis prophylaxis,
rophylactic ICD placement, cautions about the use of
chocardiographic measures of dyssynchrony in heart failure
evice therapy, the role of ultrafiltration in fluid removal,
nd additional discharge criteria.
Ray E. Hershberger (University of Miami, Miami, Flor-
da) reported on the current initiatives of a practice guide-
ine for the genetic evaluation of inheritable cardiomyopa-
hy. This complex area will be made “user friendly” by
escribing clinical phenotypes that require consideration for
enetic testing (such as a cardiomyopathy with skeletal
uscle weakness or a unique echocardiography pattern such
s left ventricular noncompaction). The single most impor-
ant recommendation may be to undertake a careful family
istory for 3 or more generations for all patients with an
idiopathic” cardiomyopathy. Topics still under active dis-
ussion include the frequency and components of genetic
creening and the therapeutic decision following such
iscovery.
Daniel J. Lenihan (MD Anderson, Houston, Texas)
resented the development of guidelines on cardiac toxicity
elated to anticancer therapy. This issue is likely to become
ncreasingly important, because cancer is no longer the
eath sentence that it once was. He highlighted proposed
uidelines for therapy before, during, and after anticancer
herapy, with a focus on recommendations that may be
ontroversial or less familiar to practitioners. Guidelines
nder active development include: recommendations for the
etection of cardiac toxicity during cancer chemotherapy by
creening for left ventricular dysfunction with echocardiog-
aphy or multiple gaited acquisition scan; blood pressure
onitoring (because new anticancer agents cause hyperten-
ion); evaluation of biomarkers such as troponin and B-type
atriuretic protein (to detect subtle cardiac injury and
tress); and the use of an angiotensin-converting enzyme
nhibitor or beta-blocker for the prevention of cardiac
oxicity before chemotherapy. Close collaboration between
ardiology and oncology is recommended to avoid the
nnecessary discontinuation of anticancer therapy.
Common” Rare Causes of Heart Failure
ith the increased survival of cancer patients, the role of
adiation and chemotherapy in the development of heart
ailure has become increasingly important. Similarly, be-
ause children with congenital heart disease have now
eached adulthood, the role of pediatric “cures” as a cause of
eart failure has been recognized. The treatment and
anagement of these populations were among the topics
iscussed in a session on rare causes of heart failure. Barry L.
aron (Mayo Clinic, Rochester, Minnesota) discussed that Trradiation is injurious to the cardiac structure and is
articularly an issue in the treatment of lymphomas and
reast, lung, and esophageal cancer, although the effect
aries by type of cancer. A review of meta-analyses, ran-
omized controlled trials, and registry data of breast cancer
urvivors treated with pre-modern techniques showed an
ncrease in cardiovascular death, all-cause mortality, or fatal
yocardial infarction. The data on cardiovascular morbidity
nd mortality in breast cancer survivors irradiated with
odern techniques are mixed: some studies show an effect,
hereas others show none. The case for the injurious effect
s more conclusive with lymphoma survivors. Lymphoma
atients are younger when treated and receive more radia-
ion exposure to the heart. Overall, conclusions about the
ignificance of radiation-induced cardiac disease are con-
ounded by factors such as the location of the tumor in
elation to the heart, whether chemotherapy is involved, the
mount of cardiac tissue in the radiation field and cardiac
rotective maneuvers. However, Dr. Karon concluded that
adiation affects all cardiac structures, there is a long latency
eriod, the risk is increased by cardiotoxic chemotherapy
nd the presence of conventional risk factors, and there are
ncreased risks associated with performing cardiac surgery
n these patients.
In his talk on adults with congenital heart disease and
eart failure, John T. Berger (Children’s National Medical
enter, Washington, DC) said the prevalence of congenital
eart disease patients is increasing as more patients are
iagnosed and corrective surgeries enable these patients to
ive into adulthood. Studies suggest that approximately
ne-fourth of patients go on to develop heart failure late
fter congenital heart surgery. Dr. Berger focused on single
entricle abnormality and the impact of various surgical
orrection strategies on the later development of heart
ailure. Current thinking is that heart failure can be pre-
ented or minimized with different surgical methods. How-
ver, we still have questions about such issues as the role of
edications in preventing abnormal remodeling in this
ituation, the role of anticoagulants, and the specifics of
articular corrective procedures. He advocated the contin-
ed collaboration between pediatric and adult specialists as
he best way to determine the consequences of current
reatment strategies.
Jean-Bernard Durand (University of Texas, Houston,
exas) spoke on drug-induced heart disease, a topic of
uch recent interest and discussion. The leading cause of
eath of cancer survivors is secondary cancer, but cardiovas-
ular complications are close behind. More than 20 new
rugs for cancer have been approved in the past 5 years, but
he cardiovascular toxicities of chemotherapy drugs are not
aptured, evaluated, or addressed in oncology clinical trials.
urthermore, cardiovascular toxicities may be more frequent
s a result of expanded indications of approved cancer drugs.
r. Durand said that all patients with exposure to cardio-
oxic agents should be considered “at risk” for heart failure.
o maximize the potential of new cancer therapies, he
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January 22, 2008:320–7 Highlights of 2007 HFSA Scientific Meetingdvocated that cardiologists be included in oncology trial
esign and that potential cardiotoxicity be identified and
ddressed from the start.
John B. O’Connell (Northwestern University, Chicago,
llinois) spoke on viral inflammatory disease with a focus on
yocarditis. Viral myocarditis should be suspected in newly
nset heart failure in a patient without other known
omorbidities, particularly if the patient is young and has
ad antecedent flu-like symptoms. Confirming a diagnosis
f myocarditis, however, can be problematic. Biopsy is the
old standard for diagnosis, but routine biopsies for unex-
lained heart failure are not justified. Magnetic resonance
maging (MRI) may be the best imaging modality, because
normal MRI may reliably exclude myocarditis. He stressed
hat when considering treatment one must remember that
here is a high incidence of spontaneous recovery, even
hen the patient is in dire hemodynamic condition. Anti-
iral agents are currently being examined in clinical trials.
ll other options, including mechanical circulatory support,
hould be used before transplant.
ender, Hormones, and Heart Failure
session featuring basic science and clinical presentations
xamined the effect of gender differences on heart failure.
Richard D. Patten (Tufts University, Boston, Massachu-
etts) discussed estrogen-receptor signaling in the heart in
emodeling. The survival advantage of women in clinical
nd experimental studies supports the hypothesis that sex
ormones may favorably influence cardiac structure and
unction. Data from animal studies support the conclusion
hat estrogen replacement affects cardiac remodeling, but
he response depends on the nature of the hypertrophic
timulus. In response to myocardial injury, estrogen replace-
ent has the potential for benefit by decreasing infarct size
nd inhibiting cardiomyocyte apoptosis, but also the poten-
ial for harm by worsening left ventricular remodeling and
ncreasing mortality. In response to pressure overload,
strogen limits left ventricular hypertrophy by inhibiting
ardiomyocyte elongation.
Leslie A. Leinwand (University of Colorado, Boulder,
olorado) discussed the impact of phytoestrogens on car-
iomyopathy. There is increasing interest in soy dietary
roducts, which have phytoestrogens and isoflavones, and
ale mice fed the traditional soy diet tend to have a worse
ardiac phenotype with reference to myocardial infarction,
ypertrophic cardiomyopathy, and hypertension compared
ith those fed a casein diet. In a mouse model destined to
evelop hypertrophic cardiomyopathy, male mice fed a
asein diet with added phytoestrogens had reduced contrac-
ile function. The phytoestrogens also activated hypertro-
hic markers and caused fibrosis in males. Diet did not
atter as much in females. Leinwand hypothesized that
hytoestrogens impact males disproportionately because
ales do not normally have endogenous estrogens. There-ore, phytoestrogens do not have to compete with estrogens so activate genes. Thus, it may be prudent to urge caution
ith the use of soy-rich diets in men with a hypertrophic
ardiomyopathy.
Frederick A. Masoudi (University of Colorado, Denver,
olorado) presented on gender-based differences in the
resentation, care, and outcomes of heart failure. Women
ith heart failure predominately have preserved left ventric-
lar systolic function (LVSF). Heart failure with preserved
VSF is not a benign condition and is associated with
ncreased readmission and mortality and poor functional
utcomes. The lack of inclusion of women in heart failure
linical trials has led to a critical gap in the evidence base
bout the care and treatment of women with heart failure.
he gap is worse in evidence for the treatment of heart
ailure with preserved LVSF. Although women with heart
ailure tend to have better survival than men, better does not
ean good, said Dr. Masoudi, who emphasized that there is
critical need to address the evidence gap concerning
omen with heart failure.
Jalal K. Ghali (Wayne State University, Detroit, Michi-
an) concluded the session with a presentation on the
ifferences in the response to heart failure therapies between
en and women. He reviewed the clinical literature regard-
ng response of women to heart failure medical therapy,
ncluding angiotensin-converting enzyme inhibitors,
ngiotensin-receptor blockers, and beta-blockers, conclud-
ng that guidelines recommending the similar treatment of
en and women are appropriate. He concluded with the
ecommendation that consideration should be given to
onduct clinical trials of heart failure drugs exclusively in
omen or to take measures to ensure a larger representation.
valuating Drugs and Devices
or Acute Decompensated Heart Failure (ADHF)
t each annual scientific meeting, representatives of indus-
ry, government, and academia hold a joint session to
iscuss an issue of global concern in a balanced forum. The
opic at this year’s meeting concerned end points in trials of
rugs and devices for ADHF. Participants included Uri
lkayam (University of Southern California, Los Angeles,
alifornia), Mark D. Carlson (St. Jude Medical, Sylmar,
alifornia), Jay N. Cohn (University of Minnesota, Min-
eapolis, Minnesota), Clyde W. Yancy (Baylor University,
allas, Texas), Robert M. Califf (Duke University,
urham, North Carolina), James B. Young (Cleveland
linic, Cleveland, Ohio), Bram D. Zuckerman (U.S. Food
nd Drug Administration [FDA], Rockville, Maryland),
nd Abraham M. Karkowsky (FDA, Silver Spring,
aryland).
Dr. Elkayam explained that management of ADHF often
nvolves a prolonged hospital stay. Treatment of volume
verload is ineffective, and many patients are still symptom-
tic at discharge, with the result that readmissions and
ortality continue to be high after discharge. Three recenttudies of therapies for ADHF, including 2 drugs and one
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Highlights of 2007 HFSA Scientific Meeting January 22, 2008:320–7evice, all used different criteria to define efficacy. The
hallenge is how to assess the effect of new treatment on
ymptoms in patients with ADHF and how to design a
tudy to assess the effect on length of hospital stay. He posed
he question of whether a therapy for ADHF need also
mprove long-term survival.
Dr. Cohn addressed questions about the measurement of
ymptoms in clinical trials. He noted that patients present-
ng with ADHF present with a number of hemodynamic
bnormalities as well as associated signs and symptoms.
ymptoms are very difficult to objectively quantify and have
een misused during in-hospital assessment as a guide to
ong-term efficacy and as a substitute for quality of life.
owever, he noted that symptoms and hemodynamics are
orrelated and suggested monitoring hemodynamic changes
n ADHF as well as their effect on long-term outcomes.
Dr. Yancy argued that the use of hospital length of stay as
n outcome measure for treatment of ADHF was not a
ood metric. Up to one-fifth of the variation in hospital
ength of stay is due to nonmodifiable components, such as
ariation in the baseline characteristics of patients and
ariables in hospital processes and procedures. Policies on
ospital length of stay vary substantially between the U.S.
nd Europe. The presence or absence of cardiogenic shock
an also have a big impact on length-of-stay measurements.
e suggested freedom from rehospitalization as a more
linically meaningful target, although a large sample size
ay be required for assessment.
Drs. Califf and Young presented opposing viewpoints on
he question of whether therapy for ADHF should also
mprove long-term survival. Dr. Califf stated that the
reatments for other diseases, including acute coronary
yndromes, must demonstrate improvement in long-term
rognosis and, therefore, so should treatment for ADHF.
r. Young argued that the ADHF patient who presents at
he hospital with chronic congestion or acute pulmonary
dema is asking for immediate help to feel better and not
hether they will be alive in 5 years. Preventing death is not
nimportant, but we have to look at whether we have
educed pain and suffering and improved quality of life.
Dr. Zuckerman discussed the challenges for the FDA in
etermining an acceptable trial design for heart failure
evices. A randomized controlled trial is the gold standard,
ut in some cases a nonrandomized trial may be appropriate.
e said there is substantial flexibility in trial design.
owever, he also underscored the need for prospective data.
he FDA receives a lot of retrospective data and does not
now how to deal with it. Data from trials conducted
utside of the U.S. should be collected using the same
rotocol used in the U.S. trial.
Dr. Karkowsky concluded the session with a discussion of
ssues involved in designing clinical studies of drugs for
DHF. To show a mortality benefit, generally on top of
tandard care, to fulfill approval criteria, a large sample size
s needed, owing to low in-hospital mortality. Symptom-
ased outcomes pose difficulties, partly because standard nare is so good that it is difficult to show that the drug being
tudied provides superior benefit. Citing the example of
esiritide, Dr. Karkowsky said the dose response for signif-
cant dose-related adverse events should be known for all
uch therapies for ADHF.
o Why, and If Not, Why Not?
our controversies regarding the management of heart
ailure were addressed in a session that touched on blood
ressure-lowering limits, anticoagulation, coronary angiog-
aphy, and anemia treatment. Jonathan G. Howlett (Dal-
ousie University, Halifax, Canada) discussed whether
lood pressure should be lowered as far as tolerated in
atients with heart failure. There are a lot of reasons why
owering blood pressure makes sense. However, lowering
lood pressure too far may cause symptoms or syncope and
ause hypotension with resulting reduction in coronary
lood flow and increased mortality. The clinical rationale
or lower blood pressure differs for systolic and diastolic
eart failure, and the scientific literature suggests differing
argets. Dr. Howlett recommended, for patients with sys-
olic heart failure, lowering systolic blood pressure to 120
m Hg and adding spironolactone, an angiotensin-receptor
locker, or hydralazine nitrate for patients who are above
he target while on standard therapy. He added that
anaging blood pressure in patients with diastolic heart
ailure was more difficult, because they are similar to
igh-risk vascular patients. In either case, there must be
areful surveillance for side effects.
Ronald S. Freudenberger (Lehigh Valley Hospital,
llentown, Pennsylvania) examined the routine use of
nticoagulation in heart failure. We do not know enough
bout thromboembolism in heart failure to recommend the
outine use of anticoagulation, because the true risk of
hromboembolism in the absence of atrial fibrillation is
nknown. However, there is evidence that heart failure is
ikely a prothrombotic state. Results of the ATLAS (As-
essment of Treatment with Lisinopril and Survival) trial
ave demonstrated that coronary thrombosis is a frequent
echanism of death, thus providing a strong rationale for
he use of antithrombotic drugs in patients with heart
ailure. The question of what to do in clinical practice is
ifficult, given the lack of evidence. A number of trials have
tudied the use of antithrombotic treatments in heart failure
ut were not powered to provide definitive results. Dr.
reudenberger concluded that the ongoing WARCEF
Warfarin Versus Aspirin in Reduced Cardiac Ejection
raction) trial is our last hope.
Mihai Gheorghiade (Northwestern University, Chicago,
llinois) addressed recommendations regarding the use of
oronary angiography. In North America and Europe, heart
ailure is often a manifestation of coronary artery disease
CAD). Therapies to prevent the progression of CAD can
lso affect outcomes in patients with heart failure. Unfortu-
ately, the importance of CAD as a continuing contributor
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January 22, 2008:320–7 Highlights of 2007 HFSA Scientific Meetingo the progression of heart failure has been ignored. Instead,
he focus has been on left ventricular remodeling and
ysfunction. Coronary artery disease is a major contributor
o the prognosis of heart failure patients with diastolic
ysfunction and to sudden cardiac death in patients with
eart failure. Certain heart failure therapies may result in
urther damage in patients with CAD. Cardiac catheteriza-
ion is not only important in prognostication but is also
elated to the implementation of life-saving therapies in
atients with CAD and heart failure. Therefore, Dr. Gheo-
ghiade advocated the routine use of coronary angiography
n patients with heart failure.
Stefan Anker (Center for Cardiovascular Research, Ber-
in, Germany) concluded the session with a discussion of a
ontroversial issue, the treatment of anemia in heart failure.
e framed the talk by first explaining that what is consid-
red to be anemia in heart failure does not follow the
lassical definition of the term. A hemoglobin level of 12
/dl is considered to be anemia in large ongoing heart failure
tudies, whereas anemia has traditionally been defined at a
ower hemoglobin cutoff point. Treatment of anemia in
eart failure patients may be beneficial in improving quality
f life, functional capacity, or symptoms and may reduce
orbidity or mortality. Therapeutic options include blood
ransfusions, iron, and erythropoietic agents alone or in
ombination with intravenous iron therapy. Although ap-
roximately 10% to 15% of heart failure patients have
nemia, Dr. Anker cautioned against treating these patients
ith the therapies that he discussed until safety and efficacy
s shown in randomized, controlled clinical trials, which to
his date have remained evasive.
xcellence in Basic Science
highlight of the scientific meeting was the Special Sunday
cientific Session centered on the theme “Excellence in
asic Science.” This session began with a Distinguished
ecture in Basic Science by Robert J. Lefkowitz (James B.
uke Professor of Medicine, Duke University, Durham,
orth Carolina) entitled “A Brief History of Seven Trans-
embrane Receptors: New Approaches to Drug Therapy.”
n his lecture, Dr. Lefkowitz chronicled the major discov-
ries in his laboratory that have led to our current under-
tanding of how G protein-coupled receptors are activated,
urn off, and initiate cellular signaling. In recognition of the
remendous contribution to advancing our understanding of
he fundamental mechanisms in heart failure, Dr. Lefkowitz
as presented with the first annual HFSA Award in Basiccience for his passion, achievement, and integrity in
iscovery science while in the pursuit of the fundamental
echanisms that underlie heart disease.
Dr. Lefkowitz’s lecture was followed by 4 outstanding
resentations by scientific leaders in other areas of basic
cience related to heart failure: Dr. Andrew R. Marks
Columbia University, New York, New York) discussed the
ole of ryanodine receptor function and its importance in the
evelopment of heart failure and the potential therapeutic
mplications. Dr. Christine E. Seidman (Harvard Medical
chool, Boston, Massachusetts) presented data on novel
nherited diseases of the heart and their progression to heart
ailure. Dr. Jonathan Epstein (University of Pennsylvania,
hiladelphia, Pennsylvania) presented a marvelous overview
f our current understanding of the molecular mechanisms
f congenital heart disease, and the final presentation in the
ession was delivered by Dr. Jonathan S. Stamler (Duke
niversity, Durham, North Carolina), who presented excit-
ng data from his laboratory showing the novel and diverse
unction for S-nitrosylation in the heart. Overall, the session
as a tremendous success and set the tone for the entire
eeting.
From basic science to clinical care, the 11th Annual
cientific Meeting of the HFSA brought together health
are experts from various disciplines to examine one syn-
rome: heart failure. This interaction, designed to promul-
ate rapid translation of bench research to the bedside,
hould serve to prevent the development of heart failure and
mprove outcomes for those suffering from this clinical
yndrome.
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